Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma
Ovarian-type serous adenocarcinoma of the testis is an extremely rare malignant disease, and experience and evidence regarding its treatment are lacking. Herein, we describe the case of a 39-year-old man who presented with widespread metastasis in the retroperitoneal and pelvic lymph nodes after sur...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1467579/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344397915717632 |
|---|---|
| author | Rui-Zhi Liu Shuang Zhang Jing Gong Jin Yao Hao Zeng Lang He |
| author_facet | Rui-Zhi Liu Shuang Zhang Jing Gong Jin Yao Hao Zeng Lang He |
| author_sort | Rui-Zhi Liu |
| collection | DOAJ |
| description | Ovarian-type serous adenocarcinoma of the testis is an extremely rare malignant disease, and experience and evidence regarding its treatment are lacking. Herein, we describe the case of a 39-year-old man who presented with widespread metastasis in the retroperitoneal and pelvic lymph nodes after surgical resection of his right testicular tumor. Systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous adenocarcinoma, was administered, and retroperitoneal lymph node dissection and radiotherapy followed after the lesions regressed. The patient has had over 3 years of progression-free survival. This is the first case of a bevacizumab combination in this disease and indicates that bevacizumab may be an option for the treatment strategy of this rare disease. |
| format | Article |
| id | doaj-art-3ad75b05b0534163b78e0936ed1d560f |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-3ad75b05b0534163b78e0936ed1d560f2025-08-20T03:42:40ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-03-011510.3389/fonc.2025.14675791467579Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinomaRui-Zhi Liu0Shuang Zhang1Jing Gong2Jin Yao3Hao Zeng4Lang He5School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaDepartment of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Pathology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Urology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People’s Hospital, Chengdu, Sichuan, ChinaOvarian-type serous adenocarcinoma of the testis is an extremely rare malignant disease, and experience and evidence regarding its treatment are lacking. Herein, we describe the case of a 39-year-old man who presented with widespread metastasis in the retroperitoneal and pelvic lymph nodes after surgical resection of his right testicular tumor. Systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous adenocarcinoma, was administered, and retroperitoneal lymph node dissection and radiotherapy followed after the lesions regressed. The patient has had over 3 years of progression-free survival. This is the first case of a bevacizumab combination in this disease and indicates that bevacizumab may be an option for the treatment strategy of this rare disease.https://www.frontiersin.org/articles/10.3389/fonc.2025.1467579/fullovarian type tumors of testisrare tumorchemotherapybevacizumabcase report |
| spellingShingle | Rui-Zhi Liu Shuang Zhang Jing Gong Jin Yao Hao Zeng Lang He Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma Frontiers in Oncology ovarian type tumors of testis rare tumor chemotherapy bevacizumab case report |
| title | Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma |
| title_full | Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma |
| title_fullStr | Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma |
| title_full_unstemmed | Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma |
| title_short | Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma |
| title_sort | case report an ovarian epithelial type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab the treatment strategy used for ovarian serous carcinoma |
| topic | ovarian type tumors of testis rare tumor chemotherapy bevacizumab case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1467579/full |
| work_keys_str_mv | AT ruizhiliu casereportanovarianepithelialtypeserousadenocarcinomaofthetestiswastreatedusingsystemicchemotherapywithbevacizumabthetreatmentstrategyusedforovarianserouscarcinoma AT shuangzhang casereportanovarianepithelialtypeserousadenocarcinomaofthetestiswastreatedusingsystemicchemotherapywithbevacizumabthetreatmentstrategyusedforovarianserouscarcinoma AT jinggong casereportanovarianepithelialtypeserousadenocarcinomaofthetestiswastreatedusingsystemicchemotherapywithbevacizumabthetreatmentstrategyusedforovarianserouscarcinoma AT jinyao casereportanovarianepithelialtypeserousadenocarcinomaofthetestiswastreatedusingsystemicchemotherapywithbevacizumabthetreatmentstrategyusedforovarianserouscarcinoma AT haozeng casereportanovarianepithelialtypeserousadenocarcinomaofthetestiswastreatedusingsystemicchemotherapywithbevacizumabthetreatmentstrategyusedforovarianserouscarcinoma AT langhe casereportanovarianepithelialtypeserousadenocarcinomaofthetestiswastreatedusingsystemicchemotherapywithbevacizumabthetreatmentstrategyusedforovarianserouscarcinoma |